Clinical Trials Logo

Cardiac Remodeling clinical trials

View clinical trials related to Cardiac Remodeling.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03274752 Completed - Clinical trials for Myocardial Infarction

Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction

CARE-AMI
Start date: October 26, 2017
Phase: Phase 2
Study type: Interventional

This study evaluates the off-target effect of paroxetine to reverse cardiac remodeling and improve left ventricular ejection fraction in patients after acute myocardial infarction. Half of the participants will receive paroxetine, while the other half will receive placebo treatment.

NCT ID: NCT01676285 Completed - Cirrhosis Clinical Trials

Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis

CARE Cirrhosis
Start date: January 2012
Phase: Phase 3
Study type: Interventional

Cirrhotic cardiomyopathy is defined as a chronic cardiac dysfunction in patients with cirrhosis. It is suspected that this specific cardiac dysfunction contributes to the onset of complications in liver disease. The purpose of this prospective, randomized trial is to determine whether metoprolol succinate can revert cardiac dysfunction secondary to cirrhosis (cirrhotic cardiomyopathy), and prevent complications (renal dysfunction, mortality). A total of 100 patients with cirrhotic cardiomyopathy will be randomized (Group R) to receive metoprolol succinate or placebo; other 25 patients without cirrhotic cardiomyopathy (Group F) will only be followed up without medication. All patients will be evaluated in the beginning and again after six months. The assessment protocol includes clinical evaluation, electrocardiogram, echocardiogram, laboratory analysis and life quality questionaire. The end points will be cardiac remodeling, electrophysiologic changes, sympathetic activity, laboratory issue changes, renal function, quality of life, and mortality.